Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check5 days agoChange DetectedNapoli, Italy, 80131 was replaced with Naples, Italy, 80131 in the locations section.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedRevision: v3.4.2 was added to replace Revision: v3.4.1 on the page. This appears to be a minor site version update not affecting study details.SummaryDifference0.0%

- Check56 days agoChange DetectedFooter revision updated from v3.4.0 to v3.4.1. The change is a minor deployment note and does not modify study content, navigation, or displayed data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThis update adds a glossary toggle and a revision label (v3.4.0), and adjusts QC-related headers and FEAR Act terminology.SummaryDifference0.1%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.